Immune-Related Toxicity: Not always the Culprit

Authors

  • Ana Cardeña Gutiérrez Ana Cardeña Gutiérrez, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain Author
  • Daniel Riado Minguez Gastroenterology Department. H. Universitario Fundación Alcorcón, Madrid, Spain Author
  • Mónica Esteban García Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain Author
  • Elena García García Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain Author
  • Xabier Mielgo Rubio Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain Author

DOI:

https://doi.org/10.47363/JCBR/2021(3)134

Keywords:

Immune-Related, Toxicity

Abstract

A 64-year-old man without any previous illness was diagnosed in May 2020 from stage IV lung adenocarcinoma. No driver mutation was found but with PDL-1>50% we could start first line Pembrolizumab 200 mg/3weekly, with great tolerance and partial response after three cycles. He only presented grade 1 emesis on day +1 after each cycle, but we did not relate it with immunotherap

Author Biographies

  • Ana Cardeña Gutiérrez, Ana Cardeña Gutiérrez, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

    Ana Cardeña Gutiérrez  Ana Cardeña Gutiérrez, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

  • Daniel Riado Minguez, Gastroenterology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

    Daniel Riado Minguez  Gastroenterology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

  • Mónica Esteban García, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

    Mónica Esteban García Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

  • Elena García García, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

    Elena García García Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain 

  • Xabier Mielgo Rubio, Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

     Xabier Mielgo Rubio Medical Oncology Department. H. Universitario Fundación Alcorcón, Madrid, Spain

Downloads

Published

2021-07-31

Issue

Vol. 3 No. 3 (2021): Volume 3 Issue 3

Section

Articles